AXSOME THERAPEUTICS, INC. Selling, General and Administrative Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Selling, General and Administrative Expense of $208.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $208.14M, a 59.76% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $185.00M, a 53.16% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $169.30M, a 49.46% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $150.24M, a 57.21% increase year-over-year.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $570.60M, a 38.71% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $411.36M, a 27.31% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $323.12M, a 102.90% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $159.25M, a 138.96% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $208.14M 10-Q · filed 2026-08-10 | $393.13M 10-Q · filed 2026-08-10 | $562.43M derived: sum of 3 quarters · filed 2026-08-10 | $712.66M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $185.00M 10-Q · filed 2026-05-04 | $354.29M derived: sum of 2 quarters · filed 2026-05-04 | $504.53M derived: sum of 3 quarters · filed 2026-05-04 | $634.81M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $169.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $319.53M derived: sum of 2 quarters · filed 2026-02-23 | $449.81M derived: sum of 3 quarters · filed 2026-08-10 | $570.60M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $150.24M 10-Q · filed 2025-11-03 | $280.51M derived: sum of 2 quarters · filed 2026-08-10 | $401.30M 10-Q · filed 2025-11-03 | $514.57M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $130.28M 10-Q · filed 2026-08-10 | $251.07M 10-Q · filed 2026-08-10 | $364.34M derived: sum of 3 quarters · filed 2026-08-10 | $459.90M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $120.79M 10-Q · filed 2026-05-04 | $234.06M derived: sum of 2 quarters · filed 2026-05-04 | $329.62M derived: sum of 3 quarters · filed 2026-05-04 | $433.18M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $113.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $208.84M derived: sum of 2 quarters · filed 2026-02-23 | $312.39M derived: sum of 3 quarters · filed 2026-02-23 | $411.36M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $95.56M 10-Q · filed 2025-11-03 | $199.12M derived: sum of 2 quarters · filed 2025-11-03 | $298.09M 10-Q · filed 2025-11-03 | $384.90M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-06-30 | $103.55M 10-Q · filed 2025-08-04 | $202.52M 10-Q · filed 2025-08-04 | $289.33M derived: sum of 3 quarters · filed 2026-02-23 | $372.52M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-03-31 | $98.97M 10-Q · filed 2025-05-05 | $185.78M derived: sum of 2 quarters · filed 2026-02-23 | $268.97M derived: sum of 3 quarters · filed 2026-02-23 | $347.90M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | $86.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $170.00M derived: sum of 2 quarters · filed 2026-02-23 | $248.93M derived: sum of 3 quarters · filed 2026-02-23 | $323.12M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | $83.19M 10-Q · filed 2024-11-12 | $162.12M derived: sum of 2 quarters · filed 2024-11-12 | $236.31M 10-Q · filed 2024-11-12 | $297.81M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-06-30 | $78.94M 10-Q · filed 2024-08-05 | $153.13M 10-Q · filed 2024-08-05 | $214.62M derived: sum of 3 quarters · filed 2025-02-18 | $255.52M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2023-03-31 | $74.19M 10-Q · filed 2024-05-06 | $135.69M derived: sum of 2 quarters · filed 2025-02-18 | $176.58M derived: sum of 3 quarters · filed 2025-02-18 | $207.74M derived: sum of 4 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $61.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $102.39M derived: sum of 2 quarters · filed 2025-02-18 | $133.55M derived: sum of 3 quarters · filed 2025-02-18 | $159.25M 10-K · filed 2025-02-18 | $159.25M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $40.89M 10-Q · filed 2023-11-06 | $40.89M 10-Q · filed 2022-11-07 | $72.05M derived: sum of 2 quarters · filed 2023-11-06 | $97.76M 10-Q · filed 2023-11-06 | $97.76M 10-Q · filed 2022-11-07 | $116.58M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-06-30 | $31.16M 10-Q · filed 2023-08-07 | $31.16M 10-Q · filed 2022-08-09 | $56.86M 10-Q · filed 2023-08-07 | $56.86M 10-Q · filed 2022-08-09 | $75.69M derived: sum of 3 quarters · filed 2024-02-23 | $95.92M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-03-31 | $25.70M 10-Q · filed 2023-05-09 | $44.53M derived: sum of 2 quarters · filed 2024-02-23 | $64.76M derived: sum of 3 quarters · filed 2024-02-23 | $81.10M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $18.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $39.05M derived: sum of 2 quarters · filed 2024-02-23 | $55.40M derived: sum of 3 quarters · filed 2024-02-23 | $66.65M 10-K · filed 2024-02-23 | $66.65M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $20.23M 10-Q · filed 2022-11-07 | $36.57M derived: sum of 2 quarters · filed 2022-11-07 | $47.82M 10-Q · filed 2022-11-07 | |||||
| 2021-06-30 | $16.34M 10-Q · filed 2022-08-09 | $27.59M 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | $28.90M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |